American Society of Clinical Oncology

Latest stories

11h
Business Wire
Genentech Highlights Personalized Medicines and Cancer Immunotherapies at 2016 American Society of Clinical Oncology (ASCO) Annual MeetingROG; OTCQX: RHHBY) today announced new results from 19 approved and investigati
Genentech Highlights Personalized Medicines and Cancer Immunotherapies at 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
Business Wire / Posted 11 hours ago
ROG; OTCQX: RHHBY) today announced new results from 19 approved and investigational medicines will be presented during the American Society of Clinical Oncology (ASCO) Annual Meeting from June 3 - 7 in Chicago. More than 200 abstracts have been... Read more
3d
FOX Business
Why ImmunoGen, Inc. Was Down Today (Hint: It Wasn't Earnings)of phase 1 patients who would be eligible for the new phase 3 had a higher resp
Why ImmunoGen, Inc. Was Down Today (Hint: It Wasn't Earnings)
FOX Business / Posted 3 days ago
of phase 1 patients who would be eligible for the new phase 3 had a higher response rate; but we'll have to wait until the American Society of Clinical Oncology (ASCO) meeting in June to see the breakdown of the data. Now what: This summer,... Read more
3d
FOX Business
Why ImmunoGen, Inc. Was Down Today (Hint: It Wasn't Earnings)of phase 1 patients who would be eligible for the new phase 3 had a higher resp
Why ImmunoGen, Inc. Was Down Today (Hint: It Wasn't Earnings)
FOX Business / Posted 3 days ago
of phase 1 patients who would be eligible for the new phase 3 had a higher response rate; but we'll have to wait until the American Society of Clinical Oncology (ASCO) meeting in June to see the breakdown of the data. Now what: This summer,... Read more
4d
WGRZ-TV Buffalo
AbbVie to buy Stemcentrx in $5.8B cash and stock dealAbbVie said. Long-term data on Rova-T, including overall survival results, is
AbbVie to buy Stemcentrx in $5.8B cash and stock deal
WGRZ-TV Buffalo / Posted 4 days ago
AbbVie said. Long-term data on Rova-T, including overall survival results, is scheduled to be presented at the 2016 American Society of Clinical Oncology annual meeting in early June, AbbVie said. AbbVie CEO and Chairman Richard Gonzalez... Read more
32 related stories
4d
WZZM 13 Grand Rapids
AbbVie to buy Stemcentrx in $5.8B cash and stock dealAbbVie said. Long-term data on Rova-T, including overall survival results, is
AbbVie to buy Stemcentrx in $5.8B cash and stock deal
WZZM 13 Grand Rapids / Posted 4 days ago
AbbVie said. Long-term data on Rova-T, including overall survival results, is scheduled to be presented at the 2016 American Society of Clinical Oncology annual meeting in early June, AbbVie said. AbbVie CEO and Chairman Richard Gonzalez... Read more
32 related stories
4d
KTVB Boise
AbbVie to buy Stemcentrx in $5.8B cash and stock dealAbbVie said. Long-term data on Rova-T, including overall survival results, is
AbbVie to buy Stemcentrx in $5.8B cash and stock deal
KTVB Boise / Posted 4 days ago
AbbVie said. Long-term data on Rova-T, including overall survival results, is scheduled to be presented at the 2016 American Society of Clinical Oncology annual meeting in early June, AbbVie said. AbbVie CEO and Chairman Richard Gonzalez... Read more
32 related stories
4d
KVUE-TV Austin
AbbVie to buy Stemcentrx in $5.8B cash and stock dealAbbVie said. Long-term data on Rova-T, including overall survival results, is
AbbVie to buy Stemcentrx in $5.8B cash and stock deal
KVUE-TV Austin / Posted 4 days ago
AbbVie said. Long-term data on Rova-T, including overall survival results, is scheduled to be presented at the 2016 American Society of Clinical Oncology annual meeting in early June, AbbVie said. AbbVie CEO and Chairman Richard Gonzalez... Read more
32 related stories
4d
WCSH 6 Portland
AbbVie to buy Stemcentrx in $5.8B cash and stock dealAbbVie said. Long-term data on Rova-T, including overall survival results, is
AbbVie to buy Stemcentrx in $5.8B cash and stock deal
WCSH 6 Portland / Posted 4 days ago
AbbVie said. Long-term data on Rova-T, including overall survival results, is scheduled to be presented at the 2016 American Society of Clinical Oncology annual meeting in early June, AbbVie said. AbbVie CEO and Chairman Richard Gonzalez... Read more
32 related stories
4d
WXIA-TV Atlanta
AbbVie to buy Stemcentrx in $5.8B cash and stock dealAbbVie said. Long-term data on Rova-T, including overall survival results, is
AbbVie to buy Stemcentrx in $5.8B cash and stock deal
WXIA-TV Atlanta / Posted 4 days ago
AbbVie said. Long-term data on Rova-T, including overall survival results, is scheduled to be presented at the 2016 American Society of Clinical Oncology annual meeting in early June, AbbVie said. AbbVie CEO and Chairman Richard Gonzalez... Read more
32 related stories
4d
WTSP-TV Tampa
AbbVie to buy Stemcentrx in $5.8B cash and stock dealAbbVie said. Long-term data on Rova-T, including overall survival results, is
AbbVie to buy Stemcentrx in $5.8B cash and stock deal
WTSP-TV Tampa / Posted 4 days ago
AbbVie said. Long-term data on Rova-T, including overall survival results, is scheduled to be presented at the 2016 American Society of Clinical Oncology annual meeting in early June, AbbVie said. AbbVie CEO and Chairman Richard Gonzalez... Read more
32 related stories
4d
WHAS TV11 Louisville
AbbVie to buy Stemcentrx in $5.8B cash and stock dealAbbVie said. Long-term data on Rova-T, including overall survival results, is
AbbVie to buy Stemcentrx in $5.8B cash and stock deal
WHAS TV11 Louisville / Posted 4 days ago
AbbVie said. Long-term data on Rova-T, including overall survival results, is scheduled to be presented at the 2016 American Society of Clinical Oncology annual meeting in early June, AbbVie said. AbbVie CEO and Chairman Richard Gonzalez... Read more
32 related stories
4d
WWL-TV, Channel 4 New Orleans
AbbVie to buy Stemcentrx in $5.8B cash and stock dealAbbVie said. Long-term data on Rova-T, including overall survival results, is
AbbVie to buy Stemcentrx in $5.8B cash and stock deal
WWL-TV, Channel 4 New Orleans / Posted 4 days ago
AbbVie said. Long-term data on Rova-T, including overall survival results, is scheduled to be presented at the 2016 American Society of Clinical Oncology annual meeting in early June, AbbVie said. AbbVie CEO and Chairman Richard Gonzalez... Read more
32 related stories
4d
WLTX-TV Columbia
AbbVie to buy Stemcentrx in $5.8B cash and stock dealAbbVie said. Long-term data on Rova-T, including overall survival results, is
AbbVie to buy Stemcentrx in $5.8B cash and stock deal
WLTX-TV Columbia / Posted 4 days ago
AbbVie said. Long-term data on Rova-T, including overall survival results, is scheduled to be presented at the 2016 American Society of Clinical Oncology annual meeting in early June, AbbVie said. AbbVie CEO and Chairman Richard Gonzalez... Read more
32 related stories
4d
WLBZ Bangor
AbbVie to buy Stemcentrx in $5.8B cash and stock dealAbbVie said. Long-term data on Rova-T, including overall survival results, is
AbbVie to buy Stemcentrx in $5.8B cash and stock deal
WLBZ Bangor / Posted 4 days ago
AbbVie said. Long-term data on Rova-T, including overall survival results, is scheduled to be presented at the 2016 American Society of Clinical Oncology annual meeting in early June, AbbVie said. AbbVie CEO and Chairman Richard Gonzalez... Read more
32 related stories
4d
WKYC Cleveland
AbbVie to buy Stemcentrx in $5.8B cash and stock dealAbbVie said. Long-term data on Rova-T, including overall survival results, is
AbbVie to buy Stemcentrx in $5.8B cash and stock deal
WKYC Cleveland / Posted 4 days ago
AbbVie said. Long-term data on Rova-T, including overall survival results, is scheduled to be presented at the 2016 American Society of Clinical Oncology annual meeting in early June, AbbVie said. AbbVie CEO and Chairman Richard Gonzalez... Read more
32 related stories
4d
13 WMAZ Macon
AbbVie to buy Stemcentrx in $5.8B cash and stock dealAbbVie said. Long-term data on Rova-T, including overall survival results, is
AbbVie to buy Stemcentrx in $5.8B cash and stock deal
13 WMAZ Macon / Posted 4 days ago
AbbVie said. Long-term data on Rova-T, including overall survival results, is scheduled to be presented at the 2016 American Society of Clinical Oncology annual meeting in early June, AbbVie said. AbbVie CEO and Chairman Richard Gonzalez... Read more
32 related stories
4d
NorthWest Cable News
AbbVie to buy Stemcentrx in $5.8B cash and stock dealAbbVie said. Long-term data on Rova-T, including overall survival results, is
AbbVie to buy Stemcentrx in $5.8B cash and stock deal
NorthWest Cable News / Posted 4 days ago
AbbVie said. Long-term data on Rova-T, including overall survival results, is scheduled to be presented at the 2016 American Society of Clinical Oncology annual meeting in early June, AbbVie said. AbbVie CEO and Chairman Richard Gonzalez... Read more
32 related stories
4d
KTHV Little Rock
AbbVie to buy Stemcentrx in $5.8B cash and stock dealAbbVie said. Long-term data on Rova-T, including overall survival results, is
AbbVie to buy Stemcentrx in $5.8B cash and stock deal
KTHV Little Rock / Posted 4 days ago
AbbVie said. Long-term data on Rova-T, including overall survival results, is scheduled to be presented at the 2016 American Society of Clinical Oncology annual meeting in early June, AbbVie said. AbbVie CEO and Chairman Richard Gonzalez... Read more
32 related stories
4d
KING5 Seattle
AbbVie to buy Stemcentrx in $5.8B cash and stock dealAbbVie said. Long-term data on Rova-T, including overall survival results, is
AbbVie to buy Stemcentrx in $5.8B cash and stock deal
KING5 Seattle / Posted 4 days ago
AbbVie said. Long-term data on Rova-T, including overall survival results, is scheduled to be presented at the 2016 American Society of Clinical Oncology annual meeting in early June, AbbVie said. AbbVie CEO and Chairman Richard Gonzalez... Read more
32 related stories
4d
First Coast News
AbbVie to buy Stemcentrx in $5.8B cash and stock dealAbbVie said. Long-term data on Rova-T, including overall survival results, is
AbbVie to buy Stemcentrx in $5.8B cash and stock deal
First Coast News / Posted 4 days ago
AbbVie said. Long-term data on Rova-T, including overall survival results, is scheduled to be presented at the 2016 American Society of Clinical Oncology annual meeting in early June, AbbVie said. AbbVie CEO and Chairman Richard Gonzalez... Read more
32 related stories
4d
KGW Channel 8 Portland
AbbVie to buy Stemcentrx in $5.8B cash and stock dealAbbVie said. Long-term data on Rova-T, including overall survival results, is
AbbVie to buy Stemcentrx in $5.8B cash and stock deal
KGW Channel 8 Portland / Posted 4 days ago
AbbVie said. Long-term data on Rova-T, including overall survival results, is scheduled to be presented at the 2016 American Society of Clinical Oncology annual meeting in early June, AbbVie said. AbbVie CEO and Chairman Richard Gonzalez... Read more
32 related stories
4d
KENS 5 San Antonio
AbbVie to buy Stemcentrx in $5.8B cash and stock dealAbbVie said. Long-term data on Rova-T, including overall survival results, is
AbbVie to buy Stemcentrx in $5.8B cash and stock deal
KENS 5 San Antonio / Posted 4 days ago
AbbVie said. Long-term data on Rova-T, including overall survival results, is scheduled to be presented at the 2016 American Society of Clinical Oncology annual meeting in early June, AbbVie said. AbbVie CEO and Chairman Richard Gonzalez... Read more
32 related stories
4d
5KSDK St. Louis
AbbVie to buy Stemcentrx in $5.8B cash and stock dealAbbVie said. Long-term data on Rova-T, including overall survival results, is
AbbVie to buy Stemcentrx in $5.8B cash and stock deal
5KSDK St. Louis / Posted 4 days ago
AbbVie said. Long-term data on Rova-T, including overall survival results, is scheduled to be presented at the 2016 American Society of Clinical Oncology annual meeting in early June, AbbVie said. AbbVie CEO and Chairman Richard Gonzalez... Read more
32 related stories
7d
News-Medical-Net
High doses of commonly-used chemotherapy drug may increase survival rate of ALL patientsPrior to the release of the initial study results, which were first presented l
High doses of commonly-used chemotherapy drug may increase survival rate of ALL patients
News-Medical-Net / Posted 7 days ago
Prior to the release of the initial study results, which were first presented last year at the annual meeting of the American Society of Clinical Oncology (ASCO), the standard of care for high-risk ALL patients in North America was escalating... Read more
8d
FOX Business
Ignore MannKind Corp.: Here Are 3 Better Stocksis so far promising, patients will want to keep their eyes open for presentatio
Ignore MannKind Corp.: Here Are 3 Better Stocks
FOX Business / Posted 8 days ago
is so far promising, patients will want to keep their eyes open for presentations the company has scheduled at this June's American Society of Clinical Oncology meeting.More hints the groundbreaking technology of Ziopharm and Intrexon could... Read more
8d
FOX Business
Ignore MannKind Corp.: Here Are 3 Better Stocksis so far promising, patients will want to keep their eyes open for presentatio
Ignore MannKind Corp.: Here Are 3 Better Stocks
FOX Business / Posted 8 days ago
is so far promising, patients will want to keep their eyes open for presentations the company has scheduled at this June's American Society of Clinical Oncology meeting.More hints the groundbreaking technology of Ziopharm and Intrexon could... Read more
8d
ScienceBlogs
Yet again, acupuncture does not work for menopausal hot flashesof Print late last month and even featured a a couple of weeks ago in the ASCO
Yet again, acupuncture does not work for menopausal hot flashes
ScienceBlogs / Posted 8 days ago
of Print late last month and even featured a a couple of weeks ago in the ASCO Connection, which is the news outlet of the American Society of Clinical Oncology, one of the largest oncology professional societies in the world. AcCliMaT is what we... Read more
11d
Channel NewsAsia
Celebrity news stories may shape women's breast cancer choicesReuters Health. Reliable sources of information include the National Cancer In
Celebrity news stories may shape women's breast cancer choices
Channel NewsAsia / Posted 11 days ago
Reuters Health. Reliable sources of information include the National Cancer Institute (http://www.cancer.gov/) and the American Society of Clinical Oncology (http://www.asco.org/), according to Sabel. "I would say it’s important to get... Read more
6 related stories
12d
Business Wire
WIN 2016シンポジウム「がん患者の転帰を改善する革新的アプローチ」を米国臨床腫瘍学会が支持2016シンポジウムは、この種のイベントとしては唯一、学界から産業界までのがんケア関係者すべてがそれぞれの最新成果を発表できる場です。 本プログラムはASC
WIN 2016シンポジウム「がん患者の転帰を改善する革新的アプローチ」を米国臨床腫瘍学会が支持
Business Wire / Posted 12 days ago
2016シンポジウムは、この種のイベントとしては唯一、学界から産業界までのがんケア関係者すべてがそれぞれの最新成果を発表できる場です。 本プログラムはASCO®の支持を受けています。ASCO®およびAmerican Society of Clinical... Read more
117 related stories
13d
National Post
Story | Business Wire News Releases | News | Financial Postque son symposium, dédié aux "Approches novatrices permettant d'améliorer la su
Story | Business Wire News Releases | News | Financial Post
National Post / Posted 13 days ago
que son symposium, dédié aux "Approches novatrices permettant d'améliorer la survie des patients", a été accrédité par la American Society of Clinical Oncology (ASCO®) pour la qualité exceptionnelle de son programme scientifique. "Pour la 8e... Read more
403 related stories
13d
National Post
Story | Business Wire News Releases | News | Financial Postthat its symposium dedicated to “Innovative approaches to improve cancer patien
Story | Business Wire News Releases | News | Financial Post
National Post / Posted 13 days ago
that its symposium dedicated to “Innovative approaches to improve cancer patient outcomes” has been endorsed by the American Society of Clinical Oncology (ASCO®) for its exceptional scientific program. “It is the 8th consecutive year that... Read more
13d
Business Wire
Merck Statement on Blueprint Project Findings Presented at the American Association for Cancer Research 2016 Annual MeetingResearch 2016 Annual Meeting. In March 2015, the AACR in partnership with the
Merck Statement on Blueprint Project Findings Presented at the American Association for Cancer Research 2016 Annual Meeting
Business Wire / Posted 13 days ago
Research 2016 Annual Meeting. In March 2015, the AACR in partnership with the U.S. Food and Drug Administration and the American Society of Clinical Oncology held a one-day workshop to examine whether multiple companion diagnostics intended for... Read more
2 related stories
13d
Newsmax
Drug Extends Life for Melanoma Patientsmelanoma. However, it is expensive, costing more than $103,000 over seven month
Drug Extends Life for Melanoma Patients
Newsmax / Posted 13 days ago
melanoma. However, it is expensive, costing more than $103,000 over seven months, according to a 2015 presentation at the American Society of Clinical Oncology. The drug is covered by most insurance plans, including Medicare, after an initial... Read more
29 related stories
16d
Orlando Sentinel
Marriage may be a cancer fightermay be a major component of the improved survival for these patients," said Mas
Marriage may be a cancer fighter
Orlando Sentinel / Posted 16 days ago
may be a major component of the improved survival for these patients," said Masters, an expert on patient care for the American Society of Clinical Oncology. "It suggests that a concerted effort to evaluate a patient's psychosocial resources... Read more
16d
San Antonio Express-News
The Obama Administration's Newly Implemented Plan to Curb Medicare Drug Inflationbe an influencing agent for physicians. Yet there are a handful of possible do
The Obama Administration's Newly Implemented Plan to Curb Medicare Drug Inflation
San Antonio Express-News / Posted 16 days ago
be an influencing agent for physicians. Yet there are a handful of possible downsides to this CMS proposal that the American Society of Clinical Oncology, or ASCO, was more than eager to point out. Image source: National Cancer... Read more
17d
Chicago Tribune
Loss of McCormick Place East could be blow for large trade showshotel rooms, restaurants and taxis. A number of major medical conferences also
Loss of McCormick Place East could be blow for large trade shows
Chicago Tribune / Posted 17 days ago
hotel rooms, restaurants and taxis. A number of major medical conferences also use Lakeside Center, including those of the American Society of Clinical Oncology and the Radiological Society of North America. The medical professionals who attend... Read more
9 related stories
20d
Business Wire
SCRA Portfolio Company KIYATEC Announces Inaugural Scientific Advisory Board MembersAACR Richard & Hinda Rosenthal Award, an ACS Clinical Research Professor Award,
SCRA Portfolio Company KIYATEC Announces Inaugural Scientific Advisory Board Members
Business Wire / Posted 20 days ago
AACR Richard & Hinda Rosenthal Award, an ACS Clinical Research Professor Award, the 2009 Gianni Bonadonna Award from the American Society of Clinical Oncology (ASCO), the 2011 Brinker Award from the Susan G. Komen for the Cure Foundation, and the... Read more
21d
The Hill
Drug plan hit with backlashto be more comprehensive than just looking at the drug costs,” Stephen Grubbs,
Drug plan hit with backlash
The Hill / Posted 21 days ago
to be more comprehensive than just looking at the drug costs,” Stephen Grubbs, vice president of clinical affairs for the American Society of Clinical Oncology, said at a panel Monday. Some healthcare observers have described the pilot as a... Read more
21d
Orlando Sentinel
Medicare plan on payment for cancer drugs stirs battlein large numbers are saying, 'What's the most expensive way I can treat this pa
Medicare plan on payment for cancer drugs stirs battle
Orlando Sentinel / Posted 21 days ago
in large numbers are saying, 'What's the most expensive way I can treat this patient?' " said Dr. Allen Lichter, CEO of the American Society of Clinical Oncology, which represents some 20,000 U.S. cancer specialists. Medicare is making "a dreadful... Read more
16 related stories
21d
The Pekin Daily Times
Medicare plan on payment for cancer drugs stirs battlein large numbers are saying, 'What's the most expensive way I can treat this pa
Medicare plan on payment for cancer drugs stirs battle
The Pekin Daily Times / Posted 21 days ago
in large numbers are saying, 'What's the most expensive way I can treat this patient?' " said Dr. Allen Lichter, CEO of the American Society of Clinical Oncology, which represents some 20,000 U.S. cancer specialists.Medicare is making "a dreadful... Read more
16 related stories
21d
CBS News
Study links marital status to cancer riskmay be a major component of the improved survival for these patients," said Mas
Study links marital status to cancer risk
CBS News / Posted 21 days ago
may be a major component of the improved survival for these patients," said Masters, an expert on patient care for the American Society of Clinical Oncology. "It suggests that a concerted effort to evaluate a patient's psychosocial resources... Read more
14 related stories
22d
The Toledo Blade
Medicare payment plan on cancer drugs sparks furious battlein large numbers are saying, ‘What’s the most expensive way I can treat this pa
Medicare payment plan on cancer drugs sparks furious battle
The Toledo Blade / Posted 22 days ago
in large numbers are saying, ‘What’s the most expensive way I can treat this patient?‘” said Dr. Allen Lichter, CEO of the American Society of Clinical Oncology, which represents some 20,000 U.S. cancer specialists. Medicare is making “a dreadful... Read more
16 related stories
22d
KPLC Lake Charles
Marriage may be a cancer fightermay be a major component of the improved survival for these patients," said Mas
Marriage may be a cancer fighter
KPLC Lake Charles / Posted 22 days ago
may be a major component of the improved survival for these patients," said Masters, an expert on patient care for the American Society of Clinical Oncology. "It suggests that a concerted effort to evaluate a patient's psychosocial resources... Read more
14 related stories
22d
NBC News
Medicare's Cancer Drug Experiment Annoys Specialistsin large numbers are saying, 'What's the most expensive way I can treat this pa
Medicare's Cancer Drug Experiment Annoys Specialists
NBC News / Posted 22 days ago
in large numbers are saying, 'What's the most expensive way I can treat this patient?' " said Dr. Allen Lichter, CEO of the American Society of Clinical Oncology, which represents some 20,000 U.S. cancer specialists. Medicare is making "a dreadful... Read more
16 related stories
22d
WTHR Indianapolis
Medicare plan on payment for cancer drugs stirs battlein large numbers are saying, 'What's the most expensive way I can treat this pa
Medicare plan on payment for cancer drugs stirs battle
WTHR Indianapolis / Posted 22 days ago
in large numbers are saying, 'What's the most expensive way I can treat this patient?' " said Dr. Allen Lichter, CEO of the American Society of Clinical Oncology, which represents some 20,000 U.S. cancer specialists. Medicare is making "a dreadful... Read more
16 related stories
22d
Your Hometown Lima Stations
Marriage may be a cancer fightermay be a major component of the improved survival for these patients," said Mas
Marriage may be a cancer fighter
Your Hometown Lima Stations / Posted 22 days ago
may be a major component of the improved survival for these patients," said Masters, an expert on patient care for the American Society of Clinical Oncology. "It suggests that a concerted effort to evaluate a patient's psychosocial resources... Read more
14 related stories
22d
WIS News 10 Columbia
Marriage may be a cancer fightermay be a major component of the improved survival for these patients," said Mas
Marriage may be a cancer fighter
WIS News 10 Columbia / Posted 22 days ago
may be a major component of the improved survival for these patients," said Masters, an expert on patient care for the American Society of Clinical Oncology. "It suggests that a concerted effort to evaluate a patient's psychosocial resources... Read more
14 related stories
22d
KTRE Lufkin and Nacogdoches
Marriage may be a cancer fightermay be a major component of the improved survival for these patients," said Mas
Marriage may be a cancer fighter
KTRE Lufkin and Nacogdoches / Posted 22 days ago
may be a major component of the improved survival for these patients," said Masters, an expert on patient care for the American Society of Clinical Oncology. "It suggests that a concerted effort to evaluate a patient's psychosocial resources... Read more
14 related stories
22d
WALB Albany
Marriage may be a cancer fightermay be a major component of the improved survival for these patients," said Mas
Marriage may be a cancer fighter
WALB Albany / Posted 22 days ago
may be a major component of the improved survival for these patients," said Masters, an expert on patient care for the American Society of Clinical Oncology. "It suggests that a concerted effort to evaluate a patient's psychosocial resources... Read more
14 related stories
22d
KSLA-TV Shreveport
Marriage may be a cancer fightermay be a major component of the improved survival for these patients," said Mas
Marriage may be a cancer fighter
KSLA-TV Shreveport / Posted 22 days ago
may be a major component of the improved survival for these patients," said Masters, an expert on patient care for the American Society of Clinical Oncology. "It suggests that a concerted effort to evaluate a patient's psychosocial resources... Read more
14 related stories
More

People in this news